Published in Biotech Law Weekly, October 29th, 2004
BTG plans to invest in the development of this innovative therapy to expand its portfolio of therapeutic programs, particularly in the area of drug repositioning.
Under the terms of the agreement, UIC grants BTG specific exclusive rights to intellectual property and inventions related to the development of therapeutic treatment of sleep apnea, as well as rights to new...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.